Novo Nordisk Reports Positive Long-Term Data for Hemophilia A Therapy

The interim results from the open-label FRONTIER4 study followed 426 participants, including both children and adults, over a median period of up to half a year. Researchers observed low rates of mild injection-site reactions, with no clinical evidence of neutralizing antibodies. Efficacy remained robust, as approximately 71% of adolescents and adults, and 89% of children, reported zero treated bleeds during the study period. Patients also reported improved joint pain management and a reduced overall treatment burden.

Beyond the primary findings, post hoc analyses indicated that denecimig successfully restores thrombin generation to normal levels without triggering an excessive response. Novo Nordisk also shared results from the explorer10 trial, which showed an 82% reduction in bleeding rates for children treated with concizumab compared to previous on-demand therapies. Dr. Martin Holst Lange, chief scientific officer at Novo Nordisk, noted that the data strengthen the potential for denecimig to serve as a flexible preventive option for diverse patient needs. The company submitted the drug for FDA review in September 2025.